Dr Joshua Ginnane
Senior Research Officer
Working groups
Background
Josh is a public health physician (FAFPHM) and researcher passionate about health system strengthening. He completed his advanced training at the Burnet Institute and the Metro South Public Health Unit in Brisbane. Josh has completed projects in evidence synthesis, guideline development, health service evaluation and economic evaluation.
Qualifications
- 2025: Fellow of the Australasian Faculty of Public Health Medicine (FAFPHM)
- 2022: MBA, IE University, Spain
- 2016: MPH, University of Melbourne
- 2016: MD, University of Melbourne
- 2011: B Biomedicine, University of Melbourne
Positions
- 2025–present: Senior Research Officer, Burnet Institute
- 2023–2025: Public Health Registrar, Burnet Institute
- 2022–2023, Intern, OECD Paris
- 2020–2021: Public Health Registrar, MSPHU, Qld.
- 2019–2020: Locum Medical Registrar, Various Hospitals
- 2017–2018: Intern and Resident, Alfred Health, Melbourne
Awards
- 2022: Top Student – International MBA, IE Business School
- 2022: 3rd Annual Gilead Pharma Case Competition Winner
- 2022: IE3 Collaboration Award, IE Business School
- 2016: Global Scholars Award, University of Melbourne
- 2015: Andrew Colgate Newell Scholarship, University of Melbourne
- 2014: Global Health Mentoring Program Scholarship, University of Melbourne
- 2012: John Flynn Placement Program Scholarship, ACRRM
- 2009: Kwong Lee Dow Scholarship, University of Melbourne
Burnet publications
View 3 moreThe determinants of health and health status of individuals in police custody in Australia: A scoping review
PLoS ONE
Joshua F. Ginnane et al
Cost‐effectiveness of interventions for screening and management of sickle cell disease during pregnancy: A systematic review
Pregnancy
Jenny Jung et al
The cost-effectiveness of interventions used for the screening, diagnosis and management of anaemia in pregnancy: A systematic review
PLOS Global Public Health
Connor Luke Allen et al
Current projects
Eliminate Hepatitis C Australia (EC Australia)
Partnering to eliminate hepatitis C as a public health threat by 2030.
Accelerating research and progress in maternal and newborn health (ARPAN CRE)
A unique collaborative network improving outcomes for women and newborns by strengthening reproductive, maternal and newborn research across Asia and the Pacific region.
Past projects
Eliminate C (EC) Victoria partnership
A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.
PharmEC REACH study: reaching methadone users attending community pharmacies with HCV
This project assesses the effectiveness, feasibility and cost-effectiveness of nurse-led testing and treatment of hepatitis C in community pharmacies for people on opiate substitution therapy.
News and features
NHMRC 2025 success for Burnet researchers
Congratulations to Dr Johanna Fraser, head of Burnet Institute's Arbovirology working group, and Dr Hayley Bullen, Burnet co‐Head of Malaria Virulence, Drug Discovery and Resistance, on receiving NHMRC 2025 Ideas Grants.
Hepatitis C treatment in pharmacies could boost diagnosis and cure rates
